Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses.
Chronic and intermittent ischemic vascular disorders represent a burgeoning clinical challenge. Previous studies have focused on the idea that therapeutic angiogenesis strategies could alleviate tissue ischemia; however, it is now appreciated that vascular disease is not simply limited to vascular wall cells but also influenced by simultaneously occurring inflammatory responses. Our laboratory has discovered that pharmacological treatment of permanent tissue ischemia with dipyridamole significantly augments ischemic tissue reperfusion, angiogenesis, and arteriogenesis over time. We have found that the beneficial effects of dipyridamole therapy are due to its ability to increase tissue nitric oxide bioavailability that corrects tissue redox imbalance. Importantly, we have also discovered that dipyridamole treatment invoking nitric oxide (NO) production significantly downregulates various innate immune response genes during chronic ischemic tissue injury. These findings demonstrate that dipyridamole-induced production of nitrite/NO significantly decreases inflammatory responses while increasing vascular growth in ischemic tissues.
Department of Pathology, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, USA.
Christopher B
CB
Pattillo
Kai
K
Fang
Justin
J
Terracciano
Christopher G
CG
Kevil
D000818:Animals; D004176:Dipyridamole / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects* / Q000235:genetics; D007249:Inflammation / Q000517:prevention & control; D007511:Ischemia / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism; D009573:Nitrites / Q000494:pharmacology*; D015424:Reperfusion / Q000379:methods*
D009573:Nitrites; D009569:Nitric Oxide; D004176:Dipyridamole